MX2022012471A - Combinaciones de inhibidores de menina e inhibidores de cyp3a4 y métodos de uso de las mismas. - Google Patents
Combinaciones de inhibidores de menina e inhibidores de cyp3a4 y métodos de uso de las mismas.Info
- Publication number
- MX2022012471A MX2022012471A MX2022012471A MX2022012471A MX2022012471A MX 2022012471 A MX2022012471 A MX 2022012471A MX 2022012471 A MX2022012471 A MX 2022012471A MX 2022012471 A MX2022012471 A MX 2022012471A MX 2022012471 A MX2022012471 A MX 2022012471A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitors
- menin
- combinations
- methods
- cyp3a4
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063006574P | 2020-04-07 | 2020-04-07 | |
| PCT/US2021/026141 WO2021207335A1 (en) | 2020-04-07 | 2021-04-07 | Combinations of menin inhibitors and cyp3a4 inhibitors and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022012471A true MX2022012471A (es) | 2022-11-30 |
Family
ID=78023861
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022012471A MX2022012471A (es) | 2020-04-07 | 2021-04-07 | Combinaciones de inhibidores de menina e inhibidores de cyp3a4 y métodos de uso de las mismas. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12564590B2 (enExample) |
| EP (1) | EP4132932A4 (enExample) |
| JP (1) | JP2023522166A (enExample) |
| KR (1) | KR20230007359A (enExample) |
| CN (3) | CN120393025A (enExample) |
| AU (1) | AU2021252552A1 (enExample) |
| CA (1) | CA3178691A1 (enExample) |
| IL (1) | IL297039A (enExample) |
| MX (1) | MX2022012471A (enExample) |
| WO (1) | WO2021207335A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017214367A1 (en) | 2016-06-10 | 2017-12-14 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-mll interaction |
| TW202525813A (zh) | 2019-12-19 | 2025-07-01 | 比利時商健生藥品公司 | 經取代之直鏈螺環接衍生物 |
| EP4132932A4 (en) | 2020-04-07 | 2024-04-17 | Syndax Pharmaceuticals, Inc. | COMBINATIONS OF MENIN INHIBITORS AND CYP3A4 INHIBITORS AND METHODS OF USE THEREOF |
| IL308476A (en) | 2021-05-14 | 2024-01-01 | Syndax Pharmaceuticals Inc | Inhibitors of the menin-mil interaction |
| US20250152591A1 (en) * | 2022-02-04 | 2025-05-15 | Kura Oncology, Inc. | Treatment of hematological malignancies with menin inhibitors and p-glycoprotein inhibitors |
| US20250295661A1 (en) * | 2022-05-09 | 2025-09-25 | Syndax Pharmaceuticals, Inc. | Menin-mll inhibitors for the treatment of cancer |
| CN120456907A (zh) * | 2022-11-02 | 2025-08-08 | 库拉肿瘤学公司 | 急性白血病的治疗方法 |
| CN120529900A (zh) | 2022-11-24 | 2025-08-22 | 奥莱松基因组股份有限公司 | 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合 |
| WO2025106862A1 (en) * | 2023-11-17 | 2025-05-22 | Kura Oncology, Inc. | Methods of treating kit positive cancers with a menin inhibitor |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2086544C1 (ru) | 1991-06-13 | 1997-08-10 | Хоффманн-Ля Рош АГ | Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина |
| US5820915A (en) | 1996-06-27 | 1998-10-13 | Bioavailability Systems, L.L.C. | Method for the preparation of a first-pass effective citrus-derived substance and product thereof |
| US6124477A (en) | 1996-06-27 | 2000-09-26 | Bioavailability Systems, Llc | Anti-first-pass effect compounds |
| US5990154A (en) | 1997-05-30 | 1999-11-23 | Bioavailability Systems, L.L.C. | Anti-first-pass effect compounds and citrus extract |
| US6248776B1 (en) | 1997-08-26 | 2001-06-19 | Bioavailability Systems, L.L.C. | Anti-first-pass effect compounds |
| US20040058982A1 (en) | 1999-02-17 | 2004-03-25 | Bioavailability System, Llc | Pharmaceutical compositions |
| US6063809A (en) | 1997-08-26 | 2000-05-16 | Bioavailability Systems, Llc | Anti-first-pass effect compounds |
| US5993887A (en) | 1998-06-29 | 1999-11-30 | Bioavailability Systems, L.L.C. | Safe citrus juice and process for preparation |
| WO2004037827A1 (en) | 2000-10-20 | 2004-05-06 | Bioavailability Systems, Llc | Synthesis of spiro ortho esters, spiro ortho carbonates, and intermediates |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| JP2007528423A (ja) | 2004-03-11 | 2007-10-11 | セコイア、ファーマシューティカルズ、インコーポレイテッド | 耐性防止レトロウイルスプロテアーゼ阻害薬 |
| US7378441B2 (en) | 2004-05-07 | 2008-05-27 | Sequoia Pharmaceuticals, Inc. | Resistance-repellent retroviral protease inhibitors |
| US20090281114A1 (en) | 2008-05-08 | 2009-11-12 | Fabre-Kramer Pharmaceuticals, Inc. | Indolylalkyl derivatives of pyrimidinylpiperazine and metabolites thereof for treatment of anxiety, depression, and sexual dysfunction |
| CL2009001152A1 (es) | 2008-05-13 | 2009-10-16 | Array Biopharma Inc | Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa. |
| MX354412B (es) | 2011-06-10 | 2018-03-05 | Merck Patent Gmbh | Composiciones y metodos para la produccion de compuestos de pirimidina con actividad inhibidora de tirosina cinasa de bruton. |
| US8466159B2 (en) * | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| TWI599356B (zh) | 2012-09-26 | 2017-09-21 | 安羅格製藥有限責任公司 | 抑制突變型ｃ－ｋｉｔ的方法 |
| MA38260B1 (fr) | 2012-12-18 | 2018-04-30 | Almirall Sa | Nouveaux dérivés de cyclohexyl et quinuclidinyl carbamate ayant une activité d'agoniste adrénergique beta2 et une activité d'antagoniste muscarinique m3 |
| US9458124B2 (en) | 2013-02-06 | 2016-10-04 | Wayne State University | Substituted pyran derivatives |
| WO2014164543A1 (en) | 2013-03-13 | 2014-10-09 | The Regents Of The University Of Michigan | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof |
| US11596636B2 (en) | 2014-01-14 | 2023-03-07 | The Trustees Of The University Of Pennsylvania | Tailored combinatorial epigenetic therapies for P53 gain-of-function tumors |
| US20170119769A1 (en) | 2014-06-10 | 2017-05-04 | The Trustees Of The University Of Pennsylvania | Scaffolds for inhibitors of menin-mll interactions |
| AU2015301746A1 (en) * | 2014-08-13 | 2017-02-16 | Celgene Corporation | Combination therapy for treating cancer |
| CN105732636B (zh) | 2014-12-30 | 2020-04-21 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
| HK1246593A1 (zh) | 2015-06-04 | 2018-09-14 | Kura Oncology, Inc. | 用於抑制menin蛋白与mll蛋白的相互作用的方法及组合物 |
| AU2016378579A1 (en) | 2015-12-22 | 2018-06-14 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-MLL interaction |
| US10869868B2 (en) | 2016-01-26 | 2020-12-22 | Memorial Sloan Kettering Cancer Center | Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia |
| PH12018501955B1 (en) | 2016-03-16 | 2024-01-24 | Kura Oncology Inc | Bridged bicyclic inhibitors of menin-mll and methods of use |
| JP6991585B2 (ja) | 2016-05-02 | 2022-01-12 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | メニン阻害剤としてのピペリジン |
| ES2990061T3 (es) * | 2016-05-10 | 2024-11-28 | C4 Therapeutics Inc | Degronímeros espirocíclicos para la degradación de proteínas diana |
| WO2017214367A1 (en) * | 2016-06-10 | 2017-12-14 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-mll interaction |
| AU2017326006B2 (en) | 2016-09-16 | 2021-10-28 | Vitae Pharmaceuticals, LLC. | Inhibitors of the menin-MLL interaction |
| WO2018175746A1 (en) | 2017-03-24 | 2018-09-27 | Kura Oncology, Inc. | Methods for treating hematological malignancies and ewing's sarcoma |
| JP7307729B2 (ja) | 2017-12-20 | 2023-07-12 | ヤンセン ファーマシューティカ エヌ．ベー． | メニン－ｍｌｌ相互作用のエキソ－アザスピロ阻害剤 |
| JP7060694B2 (ja) * | 2018-01-18 | 2022-04-26 | アレイ バイオファーマ インコーポレイテッド | Ｒｅｔキナーゼ阻害剤としての置換ピロロ［２，３－ｄ］ピリミジン化合物 |
| EP3774731A4 (en) | 2018-03-30 | 2021-11-24 | The Regents Of The University Of Michigan | PIPERIDINE COMPOUNDS AS COVALENT MENINE INHIBITORS |
| AU2019337547A1 (en) | 2018-09-13 | 2021-03-18 | Merck Sharp & Dohme Llc | Combination of PD-1 antagonist and LAG3 antagonist for treating non-microsatellite instablity-high/proficient mismatch repair colorectal cancer |
| JP2022503792A (ja) | 2018-09-26 | 2022-01-12 | クラ オンコロジー，インク． | メニン阻害剤を用いた血液悪性腫瘍の処置 |
| SG11202106304RA (en) | 2018-12-31 | 2021-07-29 | Biomea Fusion Llc | Irreversible inhibitors of menin-mll interaction |
| EP4132932A4 (en) | 2020-04-07 | 2024-04-17 | Syndax Pharmaceuticals, Inc. | COMBINATIONS OF MENIN INHIBITORS AND CYP3A4 INHIBITORS AND METHODS OF USE THEREOF |
| US20240238291A1 (en) | 2021-05-12 | 2024-07-18 | Syndax Pharmaceuticals, Inc. | Combinations for treatment of cancer |
| IL308476A (en) | 2021-05-14 | 2024-01-01 | Syndax Pharmaceuticals Inc | Inhibitors of the menin-mil interaction |
| TW202320796A (zh) | 2021-08-11 | 2023-06-01 | 美商拜歐米富士恩股份有限公司 | 用於糖尿病的menin-mll相互作用之共價抑制劑 |
| CN118234497A (zh) | 2021-12-15 | 2024-06-21 | 丹娜-法伯癌症研究所 | 通过破坏menin-mll表观遗传复合体靶向治疗胃肠道间质瘤(gist) |
| WO2025049521A2 (en) | 2023-08-28 | 2025-03-06 | Syndax Pharmaceuticals, Inc. | Aryl ether analogs as inhibitors of the menin-mll interaction |
-
2021
- 2021-04-07 EP EP21783895.2A patent/EP4132932A4/en active Pending
- 2021-04-07 WO PCT/US2021/026141 patent/WO2021207335A1/en not_active Ceased
- 2021-04-07 CN CN202510541621.9A patent/CN120393025A/zh active Pending
- 2021-04-07 CN CN202510541711.8A patent/CN120393026A/zh active Pending
- 2021-04-07 IL IL297039A patent/IL297039A/en unknown
- 2021-04-07 MX MX2022012471A patent/MX2022012471A/es unknown
- 2021-04-07 CN CN202180040679.5A patent/CN115698013B/zh active Active
- 2021-04-07 KR KR1020227038376A patent/KR20230007359A/ko active Pending
- 2021-04-07 JP JP2022561040A patent/JP2023522166A/ja active Pending
- 2021-04-07 AU AU2021252552A patent/AU2021252552A1/en active Pending
- 2021-04-07 CA CA3178691A patent/CA3178691A1/en active Pending
- 2021-04-07 US US17/917,193 patent/US12564590B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US12564590B2 (en) | 2026-03-03 |
| CN115698013B (zh) | 2026-01-02 |
| EP4132932A1 (en) | 2023-02-15 |
| CN120393025A (zh) | 2025-08-01 |
| KR20230007359A (ko) | 2023-01-12 |
| IL297039A (en) | 2022-12-01 |
| CA3178691A1 (en) | 2021-10-14 |
| US20230165858A1 (en) | 2023-06-01 |
| EP4132932A4 (en) | 2024-04-17 |
| WO2021207335A1 (en) | 2021-10-14 |
| JP2023522166A (ja) | 2023-05-29 |
| CN120393026A (zh) | 2025-08-01 |
| AU2021252552A1 (en) | 2022-10-27 |
| CN115698013A (zh) | 2023-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022012471A (es) | Combinaciones de inhibidores de menina e inhibidores de cyp3a4 y métodos de uso de las mismas. | |
| PH12022550892A1 (en) | Bicyclic heterocycles as fgfr inhibitors | |
| MX2024014142A (es) | Novedosos inhibidores de molecula peque?a de factores de transcripcion tead | |
| PH12022551013A1 (en) | Pyridazinones as parp7 inhibitors | |
| MX2022013841A (es) | Inhibidores de la interaccion de menina-mll. | |
| PH12020551760A1 (en) | Pyridazinones as parp7 inhibitors | |
| NZ784224A (en) | Parp1 inhibitors | |
| MX2023002982A (es) | Inhibidores de la interaccion de menina-leucemia de linaje mixto. | |
| MX2022015812A (es) | Inhibidores de cisteina proteasas y sus metodos de uso. | |
| EA202091709A1 (ru) | Ингибиторы днк-пк | |
| MX2025003444A (es) | Amidas heterobiciclicas como inhibidoras del cumulo de diferenciacion 38 (cd38) | |
| PH12020550986A1 (en) | Heterocyclylamino-substituted triazoles as modulators of rho-associated protein kinase | |
| PH12017501483A1 (en) | Bicyclic heterocycles as fgfr4 inhibitors | |
| PH12019501350A1 (en) | Amino-triazolopyridine compounds and their use in treating cancer | |
| MX2018007703A (es) | Inhibidores de la interaccion de menina-linaje leucemico mixto. | |
| CR20220207A (es) | Compuestos terapéuticos y métodos de uso | |
| PH12020552214A1 (en) | Ectonucleotidase inhibitors and methods of use thereof | |
| MX2024002391A (es) | Inhibidores de indolina de kif18a. | |
| PH12019502049A1 (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
| PH12021550382A1 (en) | Tetrahydropyridopyrimidine derivatives as ahr modulators | |
| PH12021553132A1 (en) | Methods of using rad51 inhibitors for treatment of pancreatic cancer | |
| PH12021551304A1 (en) | Tyrosine kinase inhibitors, compositions and methods there of | |
| EP4674415A3 (en) | Azaquinolines as inhibitors of cd38 | |
| EA202192394A1 (ru) | Ингибиторы пути передачи сигнала notch и их применение для лечения рака | |
| WO2023097194A3 (en) | Bicyclic therapeutic compounds and methods of use in the treatment of cancer |